Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Global Projects Move Genomic Medicine to the Next Level

Genomics England is selecting companies with advanced capabilities to provide clinical interpretation for the 100K Genomes Project. NextCODE Health received top marks for its analytical capabilities across all the categories evaluated: Rare disease interpretation, secondary pipeline analysis, and cancer interpretation.

Related Books

Free with a 30 day trial from Scribd

See all

Related Audiobooks

Free with a 30 day trial from Scribd

See all

Global Projects Move Genomic Medicine to the Next Level

  1. 1. Global Projects Move Genomic Medicine to the Next Level Hannes Smarason Genome Sequencing |Personalized Medicine | Transforming Health Care
  2. 2. The Next Level in Genomic Medicine New genomics-­‐based technologies and tools are making their way into a range of exci@ng research programs and clinical studies around the world. Leading-­‐edge organiza@ons are quickly adop@ng hardware for sequencing and systems for collec@ng genomic data. Now, the focus has turned to analysis and interpreta@on – the cri@cal component necessary to gain the insights from the sequence data that will transform medicine.
  3. 3. Global Projects Employing Sequencing • Earlier this year, Genomics England announced investments for broad sequencing and analysis of 100,000 human genomes. • At the @me, Genomics England had selected Illumina as its sequencing partner and was coordina@ng resources and centers to support the effort, including resourcing for analysis and interpreta@on. [See blog post here.] • Other ini@a@ves, such as the Qatar genomics program and the ini@a@ves by Longevity and Regeneron also represent the accelerated progress in seeking medical advancements from genomic data insights. [See blog post here.]
  4. 4. Genomics England Turns to Data Analysis • This week, Genomics England announced a select group of companies with advanced capabili@es to move to the next stage of evalua@on to provide clinical interpreta@on for the 100K Genomes Project. • At the @p top was NextCODE, which received top marks by Genomics England for its analy@cal capabili@es across all the categories evaluated: rare disease interpreta@on, secondary pipeline analysis and cancer interpreta@on. [See release here.]
  5. 5. NextCODE Technology on Top • The company’s advanced Genomically-­‐Ordered Rela@onal database, or GOR, combined with its clinical and discovery interfaces offer the most advanced and reliable capabili@es to support the ambi@ous tasks undertaken by Genomics England, and are already proven at popula@on scale. [Read more on the GOR database here.]
  6. 6. ExciFng Times Ahead The coming months will be a very exci@ng @me for genomic medicine, with interpreta@on taking the spotlight as we take leaps toward the next stage of personalized medicine. Read more about NextCODE’s work here.

    Be the first to comment

    Login to see the comments

  • m2com

    Oct. 15, 2014
  • gkaul

    Nov. 4, 2014
  • AbdulMohsenAlhejaily

    Sep. 25, 2015
  • NguyenNhung17

    Jul. 2, 2016

Genomics England is selecting companies with advanced capabilities to provide clinical interpretation for the 100K Genomes Project. NextCODE Health received top marks for its analytical capabilities across all the categories evaluated: Rare disease interpretation, secondary pipeline analysis, and cancer interpretation.

Views

Total views

2,092

On Slideshare

0

From embeds

0

Number of embeds

1,509

Actions

Downloads

8

Shares

0

Comments

0

Likes

4

×